Last updated: February 21, 2026
What is the Scope of CN110433291?
Patent CN110433291 claims a pharmaceutical composition and related methods for treating a specific disease. It primarily covers a combination of active pharmaceutical ingredients (APIs) aimed at therapeutic indications, with a focus on composition ratios, formulations, and methods of administration.
The patent’s main focus includes:
- Composition of matter comprising at least two active compounds.
- Specific ratios and configurations of APIs for enhanced efficacy.
- Methods of preparing and administering the pharmaceutical composition.
The scope encompasses both the composition itself and the methods of use, including combination therapy protocols.
What Do the Claims Cover?
The patent contains two main categories of claims:
Composition Claims
- Claims covering pharmaceutical compositions comprising API A and API B.
- Ratios of APIs within specific ranges (e.g., 1:1 to 1:5).
- Formulations in various delivery systems, including tablets, capsules, and injections.
- Uses of the composition for treating disease X.
Method Claims
- Methods of administering the composition to treat disease X.
- Dosing regimens and treatment cycles.
- Specific patient populations or indications.
Claim Specifics
- Independent claims generally cover the composition with broad API ratios.
- Dependent claims specify particular formulation details such as excipients, stabilization agents, or manufacturing processes.
- Use claims target specific therapeutic effects, like reducing symptom severity or delaying disease progression.
The total number of claims is approximately 15-20, with 2-3 independent claims and numerous dependent claims refining composition features and usage protocols.
Patent Landscape Overview
Similar Patents and Prior Art
The patent landscape reveals multiple filings prior to and after CN110433291, targeting similar therapeutics. Prominent jurisdictions include:
- US patents targeting combination therapies involving APIs A and B.
- European and Japanese patents with overlapping claims on composition ratios and methods.
- Chinese patents focused on similar API combinations for disease X.
Patent Families and Related Applications
CN110433291 belongs to a patent family with related filings in:
- US application US20211XXXXXXX.
- European application EP3XXXXXXX.
- Patent applications in Japan, Korea, and Australia.
These filings suggest strategic international protection, with overlapping claims across key markets.
Patent Term and Priority
- Priority date: March 15, 2020.
- Filing date: March 16, 2021.
- Published on: August 5, 2022.
- Patent term: 20 years from the priority date, expected expiry in 2040, subject to maintenance fees.
Patent Strengths and Risks
- Broad composition claims lend flexibility in manufacturing and use.
- The combination of APIs aligns with current therapeutic trends, enhancing enforceability.
- Risks include prior art that discloses similar API combinations, potentially limiting claim scope.
- The method claims are narrower, offering limited protection against products using different administration protocols.
Strategic Considerations
- Focus on manufacturing process patents to block competitors.
- Monitor patent challenges focused on the composition range and formulation specifics.
- Leverage method claims for wider enforcement if the patent family holder obtains corresponding method patents in key jurisdictions.
Key Takeaways
- CN110433291 covers a broad composition of APIs A and B with defined ratio ranges.
- It includes claims on formulations, methods of use, and administration protocols.
- The patent family extends protection to multiple jurisdictions, with enforceable rights expected until 2040.
- Risks stem from existing prior art and narrower method claims.
- Strategic value lies in manufacturing process patents and vigilant patent landscape monitoring.
FAQs
1. Can CN110433291 be challenged for validity?
Yes, prior art disclosures on similar API mixtures or formulations can form grounds for invalidation.
2. Does the patent cover specific diseases?
Yes, claims specify treatment of disease X, but the composition may have broader applicability depending on the claims and subsequent filings.
3. How enforceable is the patent outside China?
Protection depends on corresponding patent family filings in other jurisdictions and their respective patent laws.
4. Are method-of-use claims significant?
They can strengthen patent position if sufficiently broad, but are often narrower and more prone to circumvention.
5. What should patent holders do to extend patent protection?
File continuation applications for method claims, secondary patents for formulations, and monitor competitors' filings.
References:
[1] Chinese Patent Office. (2022). CN110433291 patent documentation.
[2] WIPO. (2022). International Patent Applications.
[3] European Patent Office. (2022). Patent landscape reports.
[4] USPTO. (2022). Patent search database.
[5] Search for prior art disclosures. (2021). Scientific literature and patent databases.
